Laquinimod in Participants With Relapsing-Remitting Multiple Sclerosis with Avonex® Reference Arm
- Study Title
- BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon ־²-1a (Avonexֲ®)
- Teva Identifier
- MS-LAQ-302 | EUDRACT 2007-005450-23
- ClinicalTrials.gov Identifier
- NCT00605215
- Study Status
- Completed
- Trial Condition(s)
- Multiple Sclerosis
- Interventions
- Drug: laquinimod | Drug: placebo | Drug: Interferon ־²-1a (Avonexֲ®)
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 55 Years
- Trial Duration
- 04/01/2008 - 12/01/2011
- Phase
- Phase 3
